Claudia Stumpf1, Daniel Kaemmerer2, Elisa Neubauer1, Jörg Sänger3, Stefan Schulz1, Amelie Lupp4. 1. Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University Jena, Drackendorfer Str. 1, 07747, Jena, Germany. 2. Department of General and Visceral Surgery, Zentralklinik Bad Berka, Bad Berka, Germany. 3. Institute of Pathology and Cytology Bad Berka, Bad Berka, Germany. 4. Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University Jena, Drackendorfer Str. 1, 07747, Jena, Germany. Amelie.Lupp@med.uni-jena.de.
Abstract
PURPOSE: Lung cancer is highly prevalent and has an especially poor prognosis. Thus, new diagnostic and therapeutic targets are necessary. Two potential targets are somatostatin receptors (SST), which are overexpressed in well-differentiated neuroendocrine neoplasms, and the chemokine receptor CXCR4, which is present mainly in highly proliferative and advanced tumours. Although their expression is relatively well characterized in small cell lung cancer (SCLC), in non-small cell lung cancer (NSCLC), data on SST and CXCR4 expression are scarce and contradictory. METHODS: We comparatively evaluated 83 tumour samples from a total of 57 lung cancer patients, of which 22 had adenocarcinoma (ADC), 21 had squamous cell carcinoma (SQC), and 15 had SCLC. Samples were evaluated for SST and CXCR4 expression using immunohistochemistry with well-characterized rabbit monoclonal antibodies. RESULTS: In the samples investigated, the most prominently expressed receptors were CXCR4 and SST5. Specifically, CXCR4 was detected with high expression intensity in more than 60% of ADC samples, about 90% of SQC, and 100% of SCLC. SST5 was present in about 75% of ADC and SQC samples and in more than 90% of SCLC. Although not noticeably expressed in ADC and SQC samples, SST2 was detected in 50% of SCLC cases, with a subset of patients displaying exceptionally high expression. The comparison of the three tumour entities revealed that SCLC samples had higher SST2, SST5, and CXCR4 expression, but lower SST3 and SST1 relative to ADC or SQC samples. CONCLUSION: CXCR4 may be a promising target for diagnostics and therapy in both SCLC and NSCLC.
PURPOSE:Lung cancer is highly prevalent and has an especially poor prognosis. Thus, new diagnostic and therapeutic targets are necessary. Two potential targets are somatostatin receptors (SST), which are overexpressed in well-differentiated neuroendocrine neoplasms, and the chemokine receptor CXCR4, which is present mainly in highly proliferative and advanced tumours. Although their expression is relatively well characterized in small cell lung cancer (SCLC), in non-small cell lung cancer (NSCLC), data on SST and CXCR4 expression are scarce and contradictory. METHODS: We comparatively evaluated 83 tumour samples from a total of 57 lung cancerpatients, of which 22 had adenocarcinoma (ADC), 21 had squamous cell carcinoma (SQC), and 15 had SCLC. Samples were evaluated for SST and CXCR4 expression using immunohistochemistry with well-characterized rabbit monoclonal antibodies. RESULTS: In the samples investigated, the most prominently expressed receptors were CXCR4 and SST5. Specifically, CXCR4 was detected with high expression intensity in more than 60% of ADC samples, about 90% of SQC, and 100% of SCLC. SST5 was present in about 75% of ADC and SQC samples and in more than 90% of SCLC. Although not noticeably expressed in ADC and SQC samples, SST2 was detected in 50% of SCLC cases, with a subset of patients displaying exceptionally high expression. The comparison of the three tumour entities revealed that SCLC samples had higher SST2, SST5, and CXCR4 expression, but lower SST3 and SST1 relative to ADC or SQC samples. CONCLUSION:CXCR4 may be a promising target for diagnostics and therapy in both SCLC and NSCLC.
Authors: Patrick L Wagner; Elizabeth Hyjek; Madeline F Vazquez; Danish Meherally; Yi Fang Liu; Paul A Chadwick; Tatiana Rengifo; Gabriel L Sica; Jeffrey L Port; Paul C Lee; Subroto Paul; Nasser K Altorki; Anjali Saqi Journal: J Thorac Cardiovasc Surg Date: 2008-09-19 Impact factor: 5.209
Authors: Chiara Lambertini; Patrizia Barzaghi-Rinaudo; Lisa D'Amato; Stefan Schulz; Paolo Nuciforo; Herbert A Schmid Journal: Regul Pept Date: 2013-11-01
Authors: Karen L Reckamp; Robert A Figlin; Marie D Burdick; Steven M Dubinett; Robert M Elashoff; Robert M Strieter Journal: BMC Cancer Date: 2009-06-29 Impact factor: 4.430
Authors: Constantin Lapa; Katharina Lückerath; Martina Rudelius; Jan-Stefan Schmid; Alexander Schoene; Andreas Schirbel; Samuel Samnick; Theo Pelzer; Andreas K Buck; Saskia Kropf; Hans-Jürgen Wester; Ken Herrmann Journal: Oncotarget Date: 2016-02-23
Authors: Shreya Mehta; Philip R de Reuver; Preetjote Gill; Juliana Andrici; Lisa D'Urso; Anubhav Mittal; Nick Pavlakis; Stephen Clarke; Jaswinder S Samra; Anthony J Gill Journal: Medicine (Baltimore) Date: 2015-10 Impact factor: 1.817
Authors: Max Czajkowski; Daniel Kaemmerer; Jörg Sänger; Guido Sauter; Ralph M Wirtz; Stefan Schulz; Amelie Lupp Journal: BMC Cancer Date: 2022-07-07 Impact factor: 4.638
Authors: Rosalba Mansi; Guillaume Pierre Nicolas; Luigi Del Pozzo; Karim Alexandre Abid; Eric Grouzmann; Melpomeni Fani Journal: Molecules Date: 2020-09-11 Impact factor: 4.411